Broadcom named strategic vendor for Walmart virtualization solutions
Investing.com - Syndax Pharmaceuticals (NASDAQ: SNDX) reported second quarter EPS of $-0.83, $0.18 better than the analyst estimate of $-1.01. Revenue for the quarter came in at $37.96M versus the consensus estimate of $27.13M.
Syndax Pharmaceuticals’s stock price closed at $10.38. It is down -5.72% in the last 3 months and down -47.20% in the last 12 months.
Syndax Pharmaceuticals saw 3 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See Syndax Pharmaceuticals’s stock price’s past reactions to earnings here.
According to InvestingPro, Syndax Pharmaceuticals’s Financial Health score is "fair performance".
Check out Syndax Pharmaceuticals’s recent earnings performance, and Syndax Pharmaceuticals’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar